TMCnet News
Generex Biotechnology Announces First Patient Enrolled in the Phase II Clinical Trial of AE37 in Combination with Pembrolizumab (KeytrudaÒ) for the Treatment of Triple Negative Breast CancerMIRAMAR, Fla., Sept. 17, 2019 (GLOBE NEWSWIRE) -- Generex Biotechnology Corporation (www.generex.com) (OTCQB:GNBT) (http://www.otcmarkets.com/stock/GNBT/quote) today announced that the NSABP Foundation, Inc. (NSABP) has enrolled the first patient in the study: A Phase II Clinical Trial of Pembrolizumab in Combination with the AE37 Peptide Vaccine in Patients with Metastatic Triple Negative Breast Cancer (NSABP FB-14). The trial, conducted in conjunction with research partners Merck and the NSABP Foundation, is designed to evaluate the safety and tolerability of AE37 given in combination with KEYTRUDAÒ (pembrolizumab) as well as the objective response rate. Eric von Hofe, President of NuGenerex-ImmunoOncology commented, “This is an exciting milestone for NuGenerex Immuno-Oncology, as we have now revitalized our AE37 development program with a focus on combination therapy with checkpoint inhibitors, which are now becoming standard of care for a broad array of cancers. Combining our promising immunotherapeutic with Merck’s checkpoint inhibitor, KEYTRUDA for the treatment of triple negative breast cancer represents a novel treatment strategy for a cancer of high unmet need. Prior studies with each agent alone showed promising signs of efficacy. By combining the mechanisms of checkpoint inhibition by KEYTRUDA with the robust, long-lasting and tumor-specific T-cell activation by AE37, we hope to enhance the clinical effectiveness of the immunotherapy strategies.” Jason Terrell, MD, Chief Scientific and Medical Officer of Generex Biotechnology commented, “The start of patient enrollment represents the culmination of a committed effort by the team at NuGenerex Immuno-Oncology (formerly Antigen Express) and our research partners at the NSABP Foundation and Merck. NuGenerex Immuno-Oncology has been a pioneer on the forefront of immunotherapy for over a decade with our Ii-Key platform that ensures CD4 T-cell activation against any tumor antigen to which the Ii-Key is attached. The Ii-Key platform holds great promise, and we plan to initiate additional trials using the combination of checkpoint inhibitors with AE37 immune system activation in the field of personalized immuno-oncology to help patients in need of treatment options.” Cautionary Note Regarding Forward-Looking Statements This release and oral statements made from time to time by Generex representatives in respect of the same subject matter may contain "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. These statements can be identified by introductory words such as "expects," "plan," "believes," "will," "achieve," "anticipate," "would," "should," "subject to" or words of similar meaning, and by the fact that they do not relate strictly to historical or current facts. Forward-looking statements frequently are used in discussing potential product applications, potential collaborations, product development activities, clinical studies, regulatory submissions and approvals, and similar operating mattrs. Many factors may cause actual results to differ from forward-looking statements, including inaccurate assumptions and a broad variety of risks and uncertainties, some of which are known and others of which are not. Known risks and uncertainties include those identified from time to time in the reports filed by Generex with the Securities and Exchange Commission, which should be considered together with any forward-looking statement. No forward-looking statement is a guarantee of future results or events, and one should avoid placing undue reliance on such statements. Generex undertakes no obligation to update publicly any forward-looking statements, whether as a result of new information, future events or otherwise. Generex claims the protection of the safe harbor for forward-looking statements that is contained in the Private Securities Litigation Reform Act. About Generex Biotechnology Corp. In addition to advancing a legacy portfolio of immune-oncology assets, medical devices, and diagnostics, the Company is focused on an acquisition strategy of strategic businesses that complement existing assets and provide immediate sources of revenue and working capital. Recent acquisitions include a management services organization, a network of pharmacies, clinical laboratory, and medical device companies with new and approved products. Our newly formed, wholly-owned subsidiary, NuGenerex Distribution Solutions (NDS), integrates our MSO network with a pharmacy network, clinical diagnostic lab, durable medical equipment company (DME-IQ) and dedicated call center. About Olaregen Therapeutix About our Service-Disabled Veteran-Owned Small Business (SDVOSB) Pantheon Medical is a manufacturer of a physician friendly, “all-in-one”, integrated kit that includes plates, screws, and tools required for orthopedic surgeons and podiatrists conducting foot and ankle surgeries. Generex is developing and submitting several new product lines to the FDA which will include cannulated surgical screws, plates, and implants. About MediSource Partners Cautionary Note Regarding Forward-Looking Statements This release and oral statements made from time to time by Generex representatives in respect of the same subject matter may contain "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. These statements can be identified by introductory words such as "expects," "plan," "believes," "will," "achieve," "anticipate," "would," "should," "subject to" or words of similar meaning, and by the fact that they do not relate strictly to historical or current facts. Forward-looking statements frequently are used in discussing potential product applications, potential collaborations, product development activities, clinical studies, regulatory submissions and approvals, and similar operating matters. Many factors may cause actual results to differ from forward-looking statements, including inaccurate assumptions and a broad variety of risks and uncertainties, some of which are known and others of which are not. Known risks and uncertainties include those identified from time to time in the reports filed by Generex with the Securities and Exchange Commission, which should be considered together with any forward-looking statement. No forward-looking statement is a guarantee of future results or events, and one should avoid placing undue reliance on such statements. Generex undertakes no obligation to update publicly any forward-looking statements, whether as a result of new information, future events or otherwise. Generex claims the protection of the safe harbor for forward-looking statements that is contained in the Private Securities Litigation Reform Act. Generex Contact: Generex Biotechnology Corporation Joseph Moscato Todd Falls |